TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05311423

Intervention type: DIAGNOSTIC_TEST
Intervention: QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra
Description: Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden. A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy. Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB. For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.

Intervention type: DIAGNOSTIC_TEST
Intervention: QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra
Description: Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden. A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy. Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB. For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.

Intervention type: DIAGNOSTIC_TEST
Intervention: QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra
Description: Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden. A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy. Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB. For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.

Intervention type: DIAGNOSTIC_TEST
Intervention: QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra
Description: Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden. A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy. Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB. For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
Study: NCT05755269

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Intervention: Genotyping
Description: Undergo genotyping

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study: NCT05516121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLT-015
Description: 100 mg single dose, 200 mg single dose, 200 mg single dose once a day for two consecutive days
Study: NCT05617079

Intervention type: OTHER
Intervention: Survey
Description: an electronic survey will be conducted
Study: NCT06334458

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups
Description: Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups by developing and validating a comprehensive cancer risk prediction algorithm (CRPA) as a clinical support tool to calculate a personalized risk profile
Study: NCT05515575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Each patient will receive niraparib daily in 21-day cycles until disease progression or unacceptable toxicity. Mandatory baseline tumor biopsies will occur during study screening, if feasible.
Study: NCT06643260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piclidenoson
Description: Piclidenoson is a selective A3AR agonist, supplied as tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive control
Study: NCT06644092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigation of the Effectiveness of Physiotherapy and Rehabilitation After Osteochondral Allograft Transplantation Operation
Description: The treatment protocol to be applied to the patients after surgery was determined. The protocol includes; cold application, game ready device application, CPM device application, patellar mobilization, soft tissue mobilization application, TENS, conventional TENS and NMES application, ultrasound application, stretching exercises, strengthening exercises, mobilization exercises, balance and proprioception exercises, walking training and kinesio taping.
Study: NCT06398197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nourish Intervention then No Intervention
Description: Participants will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking. After 8 weeks, participants crossover into the No Intervention group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Intervention then Nourish Intervention
Description: Participants will receive no intervention for 8 weeks. After 8 weeks, they crossover into the Nourish Intervention group where they will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking.
Study: NCT06183021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vital pulp cryotherapy
Description: Shaved ice made from sterile distilled water will be applied around the treated tooth especially in contact with amputated pulp tissue until totally dissolves.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracanal cryotherapy
Description: After mechanical preparation, a 5-minute final irrigation with 20 mL cold saline (2.5 Centigrade degrees) will be applied using a negative pressure irrigation technique per canal.
Study: NCT04630769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP FT516
Description: FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP FT516
Description: FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP FT516
Description: FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP FT516
Description: FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP FT516
Description: FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3 which is highly expressed on ovarian cancer. Enoblituzumab at 15 mg/kg IV, one day before lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3 which is highly expressed on ovarian cancer. Enoblituzumab at 15 mg/kg IV, one day before lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is \<45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is \<45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.
Study: NCT06239428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-TREAT
Description: A 12-session internet-based cognitive behavioral intervention for Danish adolescents and adults with Other Specified Feeding or Eating Disorders.
Study: NCT04630769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is \<45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is \<45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.
Study: NCT06239428

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: A 12-week waitlist with access to online mindfulness material.
Study: NCT06367361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: Human studies have shown that doses up to 60 mg/kg (approximately 3.6 g for a 60-kg human, which is considered the average weight of an adult in developing countries) are safe and that repeated doses of 15 mg/kg (approximately 900 mg for a 60-kg human) daily for 5 days are safe. A single dose of OXF results in significant plasma drug concentrations that reach a Cmax plateau after doses of 15 mg/kg.75 The dose to be studied in this trial is 20 mg/kg (1200 mg maximum dose), a dose only slightly higher than that achieving a Cmax plateau. This dose was conservatively selected to account for interindividual variation in plasma levels and deemed well tolerated and safe based on laboratory and ECG evaluations.
Study: NCT05950217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Nurse-led patient education
Study: NCT05386173

Intervention type: PROCEDURE
Intervention: Fetal aortic balloon dilatation
Description: Fetal valvuloplasty will be performed as described in Arzt W, Wertaschnigg D, Veit I, Klement F, Gitter R, Tulzer G. Intrauterine aortic valvuloplasty in fetuses with critical aortic stenosis: experience and results of 24 procedures. Ultrasound Obstet Gynecol. 2011;37:689-695. with minor variations between centers involved. Technical success is defined as improved forward flow and/or new aortic regurgitation.
Study: NCT04630769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is \<45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.
Study: NCT05044468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Given via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Given via injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06367361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: Human studies have shown that doses up to 60 mg/kg (approximately 3.6 g for a 60-kg human, which is considered the average weight of an adult in developing countries) are safe and that repeated doses of 15 mg/kg (approximately 900 mg for a 60-kg human) daily for 5 days are safe. A single dose of OXF results in significant plasma drug concentrations that reach a Cmax plateau after doses of 15 mg/kg.75 The dose to be studied in this trial is 20 mg/kg (1200 mg maximum dose), a dose only slightly higher than that achieving a Cmax plateau. This dose was conservatively selected to account for interindividual variation in plasma levels and deemed well tolerated and safe based on laboratory and ECG evaluations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclabendazole
Description: The standard of care for the treatment of fascioliasis according to the same guidelines is two 10 mg/kg doses of TCBZ 24 hours apart administered with a fat containing meal. The subjects in one of the arms of the study will receive this treatment as the standard of care. Subjects from any of the arms that fail to achieve parasitological cure will receive rescue treatment off the study with two doses of TCBZ as recommended by the Peruvian guidelines.
Study: NCT05044468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06608303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Human Granulocyte Macrophage Stimulating Factor Gel
Description: Human granulocyte macrophage colony-stimulating factor (rhGM-CSF), as a multifunctional haematopoietic factor, stimulates the proliferation and differentiation of haematopoietic precursor cells to granulocyte macrophages and promotes their peripheral translocation, as well as enhances phagocytosis and secretion of granulocytes and macrophages \[11\]. Since macrophages are key players in regulating the inflammatory response of wounds and promoting wound repair, rhGM-CSF is thought to potentially play a positive role in the treatment of acute and chronic wounds.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: placebo
Study: NCT06037811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Participants will be randomized 1:1 (non-blinded) to receive either adalimumab (40 mg subcutaneous every 2 weeks for 12 weeks) and prednisone vs prednisone alone. Addition of methotrexate (MTX) and/or hydroxychloroquine (HCQ) is permitted, as needed, at the discretion of the treating rheumatologist. No additional conventional synthetic, targeted synthetic or biologic DMARDs are permitted during the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone as per standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone as per standard of care.
Study: NCT05697380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Bridge™
Description: Evidence-based speech language therapy treatment will be compared and contrasted.
Study: NCT05486299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic assisted single-port general surgery
Description: Robot assisted single-port rectal resection, colectomy, partial gastrectomy, appendectomy and cholecystectomy via the single-port configuration
Study: NCT06357156

Intervention type: RADIATION
Intervention: CBCT
Description: The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes.

Intervention type: RADIATION
Intervention: CBCT
Description: The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes.

Intervention type: RADIATION
Intervention: CBCT
Description: The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes.

Intervention type: RADIATION
Intervention: CBCT
Description: The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes.

Intervention type: RADIATION
Intervention: CBCT
Description: The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes.

Intervention type: RADIATION
Intervention: CBCT
Description: The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes.
Study: NCT06424691

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailored Recommendations
Description: Based on the microbiome analysis, participants will receive personalized action plans. These plans include dietary, lifestyle, and supplemental suggestions to improve their infant's gut health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consult Call
Description: Participants will have seven consult calls with a Gut Health Coach over the course of the study. These calls will provide guidance on the gut health reports, action plans, and any questions or concerns parents may have.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email Series
Description: Parents will receive a series of educational emails covering topics such as the importance of gut health, breastfeeding benefits, the impact of C-section delivery on the microbiome, and tips for introducing solid foods.
Study: NCT05777824

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anti-PD-1 or PD-L1 antibody
Description: immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anti-PD-1 or PD-L1 antibody
Description: immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anti-PD-1 or PD-L1 antibody
Description: immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy
Study: NCT05849844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanoseal
Description: All subjects will receive the Tympanoseal device that will be placed during a surgical procedure
Study: NCT05650827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 10 weeks of resistance training 3 times pr. week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement
Description: A daily supplement of protein to ensure a daily intake of 1,6g protein/kg bodyweight
Study: NCT05896202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: taVNS Video
Description: One third of the participants will see the taVNS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Participants will receive sample consent forms and brochures for taVNS and TMS. These materials will be reviewed with each participant once on site, and they will have the opportunity to ask questions. participants will take these materials home and have the opportunity to review further at their leisure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational materials
Description: Participants will receive sample consent forms and brochures for taVNS and TMS. These materials will be reviewed with each participant once on site, and they will have the opportunity to ask questions. participants will take these materials home and have the opportunity to review further at their leisure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TMS Video
Description: One third of the participants will see the TMS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.